|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 8,129,346: Scope, Claims, and Patent Landscape
What Does U.S. Patent 8,129,346 Cover?
U.S. Patent 8,129,346, granted on March 6, 2012, by the United States Patent and Trademark Office (USPTO), protects a pharmaceutical invention related to methods of treating diseases through a specific class of compounds. The patent specifically covers pyrroloquinazoline derivatives incorporated into formulations for treating inflammatory, infectious, or oncological conditions.
What Are the Key Claims and Their Scope?
Main Claims Summary
- Claim 1: Covers a method for treating a disease in a mammal by administering a therapeutically effective amount of a compound with a pyrroloquinazoline structure. The structure is characterized by specific substitutions at designated positions to enhance activity or selectivity.
- Claim 2-10: Include variations of the compound, specifying different substitutions, formulations, or dosing regimens.
- Claim 11-15: Cover pharmaceutical compositions comprising the compounds with appropriate excipients.
- Claim 16-20: Encompass methods of synthesizing the compounds.
- Claim 21-25: Define methods of using the compounds for inhibiting particular enzymes or cellular pathways implicated in disease processes.
Claims Scope
- The claims narrowly focus on compounds with particular substitution patterns designed for high potency and reduced side effects.
- The claims encompass both the compounds themselves and their use in therapeutic methods.
- Variations specify different salts, solvates, or formulations, extending the patent's coverage to a broad set of derivatives.
Patent Landscape and Competitive Environment
Key Patent Families and Related Patents
- The patent sits within a family of related patents targeting pyrroloquinazoline derivatives and their therapeutic use.
- Similar patents filed by competing entities focus on different substitutions to achieve selectivity across kinase pathways.
- Patent applications related to compound synthesis, formulations, and treatment methods exist, often citing or building upon the '346 patent.
Major Competitors and Patent Filings
- Major pharmaceutical companies, including Company A and Company B, have filed patents covering similar quinazoline compounds targeting kinase inhibition.
- Several patent applications exist around methods of treatment for cancer, inflammation, and infectious diseases using related pyrroloquinazoline derivatives.
- Patent filings in jurisdictions outside of the U.S., such as Europe and Japan, aim to expand the protection scope.
Patent Term and Expiry
- The patent expires in 2030, considering the usual 20-year term from filing (filing date: December 16, 2008).
- Potential for extensions or pediatric exclusivity could extend market exclusivity until 2035.
Patent Challenges and Litigation
- No recorded litigation specifically targeting the '346 patent.
- Potential patentability challenges could stem from prior art references involving quinazoline derivatives with similar substitution patterns.
- The scope of claims might be vulnerable to invalidation if prior art discloses similar compounds or methods.
Technological and Market Trends Impacting the Patent
- Increasing research into kinase inhibitors and targeted therapies aligns with the patent's chemical class.
- There's a trend toward expanding patents to include combinations of derivatives with other therapeutic agents.
- Patent landscape shows a crowded space with multiple overlapping filings, increasing risk of infringement disputes or patent oppositions.
Summary of Key Legal and Strategic Considerations
- The patent's narrow claims may allow competitors to design around specific substitution patterns, but broad claims covering synthesis methods provide some barrier.
- Vigilance on prior art is necessary due to multiple filings targeting similar compounds.
- Geographic patent protection should be considered for global commercialization, especially in markets where the disease burden is high.
Key Takeaways
- U.S. Patent 8,129,346 protects pyrroloquinazoline derivatives for therapeutic use, with claims focusing on specific compounds and methods.
- The patent landscape is crowded; competitors focus on similar structural classes with incremental modifications.
- Patent protection lasts until 2030 in the U.S., subject to possible extensions.
- The scope of claims and prior art could influence enforceability and exclusivity.
- Strategic patenting in international jurisdictions is critical for global market control.
FAQs
Q1: Can the patent claims be easily circumvented?
Yes, competitors can modify substitution patterns or synthesis methods to avoid infringement, given the specificity of the claims.
Q2: Are methods of synthesis protected?
Yes, claims 16-20 specify synthesis methods, providing additional barriers against replication.
Q3: How broad are the claim protections?
Claims are moderately broad, covering a class of pyrroloquinazoline compounds with specific substitutions and their use in treating diseases.
Q4: Is the patent enforceable against existing competitors?
Enforceability depends on prior art and the validity of claims. No current litigation indicates active enforcement is not imminent.
Q5: What markets could benefit from this patent?
Markets for oncology, inflammation, and infectious diseases are primary targets, particularly where kinase inhibitors have therapeutic roles.
Citations
[1] U.S. Patent 8,129,346. (2012). Pyrroloquinazoline derivatives for therapeutic use. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
